Drug Invention Today
ISSN NO: 0975-7619
Drug Invention Today (DIT) was first published in 2009 by JPR Solutions. It is a journal, which publishes reviews, research papers and short communications . 
• Novel Drug Delivery Systems • Nanotechnology & Nanomedicine • Biotechnology related pharmaceutical technology • Polymeric bio-conjugates • Biological macromolecules • Biomaterials • Drug Information • Drug discovery/development • Screening of drugs from natural & synthetic origins • Novel therapeutic strategies • Combinatorial chemistry and parallel synthesis • Clinical trials • Case Reports
 Impact FactorTM ( India ) = 0.897 as on date (08.05.2017)
  Scopus Indexed ( link http://www.scimagojr.com/journalsearch.php?q=21100202909&tip=sid&clean=0)
Journal Metrics for this   Drug Invention Today (Source ID: 21100202909): 2014 (SNIP) Source Normalized Impact Per Paper : 0.402; SCImago Journal Rank (SJR):0.301; Impact Per Publication : 0.517 (Top level : Life Science)
Indexed in
NCBI NLM Catalogue,
SCOPUS, EMBASE (Elsevier),
SCIMAGO, CAS,
ROAD, CABI, Google Scholar,
Open J-Gate, Biblioteca,
Science Central,
Index Scholar, Indian Citation Index,
 AYUSH Research Portal, 
Indexed Copernicus, EBSCO, PSOAR,
Ulrichs Directory of Periodicals, etc.

Manuscripts Published

Journal: Drug Invention Today , Volume: 3, Issue: August
Article Id: JPRS-BSN-00001085
Title: Insilico studies on the enhancing effect of anti-cancer phytochemicals of Moringa oleifera on cellular prostatic acid phosphatase activity
Category: Biomaterials ( Synthetic and Natural )
Section: Research Article
Country: India
View Article

The emergence of deadly diseases like cancer has led to novel therapies. Prostate cancer is one such disease. This study emphasizes the significance of natural products to solve pharmacological problems. Prostatic acid phosphatase (PAP) is a valuable marker and the key enzyme involved in prostate cancer. Though its secretory level increases, its cellular form decreases in prostate cancer patients. Cellular Prostatic acid phosphatase (cPAP) functions as a tyrosine phosphatase of oncoproteins associated with prostate carcinogenesis. Thus, cPAP whose expression diminishes with the progression of prostate cancer is selected as the drug target. Ligands that can enhance the activity of cPAP may have potential applications for prostate cancer therapy. Moringa oleifera is a highly valued medicinal plant. It is an effective natural resource rich in phytochemicals that can act as anti-cancer agents. This work involves an insilico study on the enhancing effect of anti-cancer phytochemicals of Moringa oleifera on the activity of cPAP. The effect is compared with that of PAP activators collected from the database and the reported standard therapeutics for prostate cancer. Bioinformatics methods are adopted for Structural analysis, Docking and Toxicity studies. The results facilitate the understanding of the use of the anti-cancer phytochemicals of Moringa oleifera as the potent and safe natural agents to assist in prostate cancer drug design.